menu
    • menu
    [{"orgOrder":0,"company":"The Biovac Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer,BioNTech Collaborate with Biovac to Manufacture, Distribute COVID-19 Vaccine Doses within Africa","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"The Biovac Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Biovac Institute \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"The Biovac Institute \/ Pfizer"},{"orgOrder":0,"company":"The Biovac Institute","sponsor":"International Vaccine Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biovac Signs Deal With IVI to Develop and Manufacture Oral Cholera Vaccine for African and Global Markets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"Cholera Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The Biovac Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The Biovac Institute \/ International Vaccine Institute","highestDevelopmentStatusID":"4","companyTruncated":"The Biovac Institute \/ International Vaccine Institute"},{"orgOrder":0,"company":"The Biovac Institute","sponsor":"Wellcome","pharmaFlowCategory":"D","amount":"$6.9 million","upfrontCash":"Undisclosed","newsHeadline":"Biovac Signs Deal With IVI to Develop and Manufacture Oral Cholera Vaccine for African and Global Markets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Funding","leadProduct":"Cholera Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The Biovac Institute","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"The Biovac Institute \/ Wellcome","highestDevelopmentStatusID":"4","companyTruncated":"The Biovac Institute \/ Wellcome"}]

    Find Clinical Drug Pipeline Developments & Deals by The Biovac Institute

    Menu

    The Biovac Institute

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            The Biovac Institute

                            South Africa arrow
                            Discovery on Target
                            Not Confirmed

                            The Biovac Institute

                            South Africa arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cholera Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : International Vaccine Institute

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Biovac Signs Deal With IVI to Develop and Manufacture Oral Cholera Vaccine for African and Global Markets

                            Details : The partnership with IVI aims to license and transfer technology with the ultimate aim of increasing production volumes of OCV (cholera vaccines) in order to reduce the critical shortage of vaccines needed to prevent cholera globally.

                            Brand Name : OCV

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            November 23, 2022

                            Lead Product(s) : Cholera Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : International Vaccine Institute

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            The Biovac Institute

                            South Africa arrow
                            Discovery on Target
                            Not Confirmed

                            The Biovac Institute

                            South Africa arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cholera Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Wellcome

                            Deal Size : $6.9 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Biovac Signs Deal With IVI to Develop and Manufacture Oral Cholera Vaccine for African and Global Markets

                            Details : IVI developed the world’s first low-cost oral cholera vaccine (OCV). The partnership with IVI aims to license and transfer technology with the ultimate aim of increasing production volumes in order to reduce the critical shortage of vaccines needed to ...

                            Brand Name : OCV

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            November 22, 2022

                            Lead Product(s) : Cholera Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Wellcome

                            Deal Size : $6.9 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            The Biovac Institute

                            South Africa arrow
                            Discovery on Target
                            Not Confirmed

                            The Biovac Institute

                            South Africa arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tozinameran

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Pfizer,BioNTech Collaborate with Biovac to Manufacture, Distribute COVID-19 Vaccine Doses within Africa

                            Details : Biovac will perform manufacturing and distribution activities within Pfizer’s and BioNTech’s Covid Vaccine, BNT162b2's global supply chain and manufacturing network, which will now span three continents and include more than 20 manufacturing faciliti...

                            Brand Name : BNT162b2

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            July 21, 2021

                            Lead Product(s) : Tozinameran

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth